Evolus, Inc. Common Stock

EOLSNASDAQUSD
4.16 USD
0.13 (3.23%)AT CLOSE (11:59 AM EDT)
4.16
0.01 (0.12%)
POST MARKET (AS OF 06:34 PM EDT)
Post Market
AS OF 06:34 PM EDT
4.16
0.01 (0.12%)
🟢Market: OPEN
Open?$4.00
High?$4.22
Low?$3.97
Prev. Close?$4.03
Volume?776.6K
Avg. Volume?1.4M
VWAP?$4.15
Rel. Volume?0.57x
Bid / Ask
Bid?$3.58 × 100
Ask?$4.79 × 100
Spread?$1.21
Midpoint?$4.19
Valuation & Ratios
Market Cap?262.2M
Shares Out?65.1M
Float?55.5M
Float %?85.8%
P/E Ratio?N/A
P/B Ratio?-11.35
EPS?-$0.79
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.90Adequate
Quick Ratio?1.54Adequate
Cash Ratio?0.71Adequate
Debt/Equity?-7.72Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A
P/B?
-11.35CHEAP
P/S?
0.88CHEAP
P/FCF?
N/A
EV/EBITDA?
-17.9CHEAP
EV/Sales?
1.30CHEAP
Returns & Efficiency
ROE?
223.5%STRONG
ROA?
-22.9%WEAK
Cash Flow & Enterprise
FCF?$-50717000
Enterprise Value?$386.6M
Related Companies
Loading...
News
Profile
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Employees
334
Market Cap
262.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2018-02-08
Address
520 NEWPORT CENTER DRIVE
NEWPORT BEACH, CA 92660
Phone: (949) 284-4555